Q4 2022 Teladoc Health Inc Earnings Call
Okay.
Good afternoon, and thank you for attending today's Teladoc fourth quarter 2022 earnings Conference call. My name is Daniel and I'll be the moderator for today's call.
All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question. Please press star followed by one on your telephone keypad. It is now my pleasure to pass the conference over to our host Patrick Feeley head of Investor Relations Patrick the floor is yours.
Thank you and good afternoon today after the market closed we issued a press release announcing our fourth quarter and full year 2022 financial results. This press release and the accompanying slide presentation are available on the Investor Relations section of the Teladoc health Dot Com website on this call to discuss the results are Jason <unk> Chief Executive Officer.
Mala Murthy, Chief Financial Officer. During this call. We will also provide our first quarter and full year 2023 outlook and our prepared remarks will be followed by a question and answer session. Please note that we'll be discussing certain non-GAAP financial measures that we believe are important in evaluating teladoc health's performance details on the relationship between these non-GAAP measures to the most comparable.
GAAP measures and reconciliations thereof can be found in the press release that is posted on our website.
Also please note that certain statements made during this call will be forward looking statements as defined by the private Securities Litigation Reform Act of 1095, such forward looking statements are subject to risks uncertainties and other factors that could cause the actual results for teladoc health to differ materially from those expressed or implied on this call for additional information. Please.
Refer to our cautionary statement in our press release, and our filings with the SEC all of which are available on our website.
Now I'd like to turn the call over to Jason.
Thank you Patrick good afternoon, and thanks for joining us.
This afternoon I'm pleased to share our strong fourth quarter results to finish what was undoubtedly a challenging year.
So today, we are providing our 2023 guidance, which reflects our balanced approach to top and bottom line growth and we will speak to changes to our reporting that will help you better track our progress.
First let's start with a brief recap of the past quarter and year.
Overall, despite a more challenging macro environment, our underlying business continues to perform with positive momentum demonstrated by our ability to continue driving solid full year revenue growth.
Fourth quarter consolidated revenue grew 15% year over year to $638 million near the high end of our guidance range for.
For the full year total revenue grew 18% to more than $2 4 billion.
Fourth quarter consolidated adjusted EBITDA of $94 million was in line with the outlook. We provided in October delivering upon our expectation for a significant margin increase in the quarter.
We're pleased with the performance of our better health business, which grew 29% year over year in the fourth quarter, while delivering on our profitability target.
We also remain excited about the momentum we're seeing for our integrated whole person platform, which includes chronic care mental health and primary 360 now all accessible through a single log in account in our new unified App.
Looking to 2023 and beyond our leadership position and whole person virtual care is clear.
The breadth and depth of our market leading portfolio of products and services provides a strong platform for growth and expansion.
I am very pleased with our progress as we continue to deliver on our mission and realize our vision of making virtual care. The first step on any health care journey.
Top of mind as we begin the new fiscal year is vendor consolidation.
We hear a growing desire from our clients to shift away from point solutions and toward multi product integrated virtual and digital platforms.
At the same time, we're seeing clients increasingly focus on demonstrated results.
Teladoc health has been at the forefront of the adoption curve and we believe that our scale breadth of product offering and proven outcomes will enable us to maintain and expand our position in the market.
While there remains a healthy demand for solutions that promise better access and outcomes, while lowering the cost of healthcare.
The challenging macro environment is likely to persist.
This is particularly the case with regard to ongoing economic uncertainty as well as a moderation in overall market growth rates.
Given the current operating environment as well as at a larger scale at which we now operate you should expect us to balance growth and margin with an increased focus on efficiency going forward.
Part of that approach is right sizing our cost structure to reflect the current growth rates of the business.
As such the management team has been working diligently on ways to optimize the cost structure of the organization, which includes beginning of the year with some tough decisions regarding layoffs and the restructuring of some genes.
This restructuring will enable us to improve efficiency, while still allowing us to effectively build upon our integrated virtual care offering in a market that remains in the early innings.
These actions are reflected in our Q1 and full year 2023 outlook.
This more balanced approach does not mean that we will stop relentlessly pursuing growth and increased adoption of virtual care across the industry.
Virtual care's role within the health care industry remains Underpenetrated, and we will continue to invest to expand our leadership position.
Our key strategic priorities remain our whole person suite of services, including our virtual primary care offering primary 360, our suite of chronic care management solutions and our mental health products.
And continued growth in our better help consumer brand.
Access to our platform is available to over 80 million individuals in the U S. Today, primarily through our relationships with employers and health plans.
Over 50% of that population has access to more than one of our products and when I look at our suite of chronic care solutions, 30% of enrollees are now utilizing more than one chronic care product.
Our better help offering provided over 1 million individuals with access to mental health care over the past year.
Many of whom are unlikely to have received any care at all if not for our services.
Our platform enabled over 22 million visits across specialties last year.
And over half a billion digital health interactions with an unmatched consumer experience and a net promoter score over 60.
That breadth and scale is unrivaled in the industry and gives us a strong foundation on which to expand.
With the more balanced approach I referenced a moment ago, we will pursue growth in a more focused way with the goal of expanding our margins consistently over the next several years as we march toward GAAP profitability, while still achieving attractive and sustainable top line growth rates.
Do you see this more balanced approach reflected in our 2023 guidance today.
For the full year 2023, we expect revenue of $2 55 to $2 $6 75 billion.
Representing year over year growth of 6% to 11%.
We expect adjusted EBITDA of $275 million to $325 million.
<unk> growth of 12% to 32%.
You'll also notice some changes in the way that we report our results in today's press release reflective of the way we are managing the business going forward.
As our better help direct to consumer brand has scaled up rapidly over the past few years. We also felt that it is the appropriate time to provide increased disclosure for this business.
As such you will now see our results reported along two segments Teladoc health integrated care, which primarily consists of our <unk> distribution channels, including business sold through employers health plans and providers, both domestically and internationally.
And better health, which primarily consists of mental health services sold through our direct to consumer distribution channel.
Malo will discuss some of the additional assumptions underpinning our guidance in a moment, including how we're thinking about performance between these two segments.
Hopefully youll find this new disclosure helpful in modeling the business going forward.
Let me end by saying the company remains strongly positioned both strategically and financially.
Our vision to deliver integrated whole person virtual care and our multi product strategy continues to resonate in the marketplace.
And from a financial perspective, we continue to generate positive free cash flow and maintain a strong balance sheet.
This is a clear differentiator for Teladoc health and provides us with the ability to invest in the expansion of our leadership position at a time when many of our smaller competitors are facing significant financial stress.
With that I will turn the call over to Mala for a review of the fourth quarter and our forward guidance.
Thank you, Jason and good afternoon, everyone.
Let's turn to the results for the quarter I want to take a moment to discuss our new reporting structure.
As Jason noted you will see in today's release that we are now reporting along two new segments.
Hello Dock health integrated care and better health.
On page seven of the press release, you will find segment results and metrics from the prior five quarters to help in your modeling.
For the integrated care segment in addition to revenue and adjusted EBITDA.
We are reporting total U S membership with access to our suite of virtual program across our <unk> distribution channels.
This combines the prior categories of paid members visit fee only members and chronic care regularly.
We believe the distinction between the member types is becoming less meaningful as the revenue models of our products have become more diverse over time.
And as we move towards more whole person bundled and value based arrangements.
Revenue per U S. Integrated care member represents total segment revenue divided by reported U S integrated care membership.
We are also providing total chronic care program enrollment, which represents the total number of program in which our members are actively enrolled.
We believe program enrollment is more reflective of growth in chronic care revenue as we continue to drive multi program enrolment among our members.
For the better health segment.
In addition to revenue and adjusted EBITDA, We are reporting total better help users, which represents the average number of monthly paying users after services during the period.
Turning to results.
During the fourth quarter consolidated revenue increased 15% year over year to $638 million.
Fourth quarter adjusted EBITDA of $94 million was in line with the outlook, we provided in October and.
And represents a $43 million increase sequentially, primarily a reflection of the advertising spend seasonality in the direct to consumer business as we have discussed throughout 2022.
Integrated care segment revenue increased 6% year over year to $357 million in the quarter, driven primarily by growth in chronic care management and telemedicine product revenue.
Integrated care added $5 8 million U S members over the prior year, representing 7% year over year growth and one 4 million sequentially to end the year with $83 3 million total U S members.
Paid members were $58 7 million for the quarter, which exceeded the high end of our prior guidance range of 57 to 58 million members.
Total chronic care program enrollment exceeded 1 million programs in the fourth quarter, representing growth of 16% over the prior years fourth quarter.
The total number of individuals enrolled in one of our chronic care programs.
805000 during the quarter and increase of 10% over the prior year's fourth quarter.
Average integrated care segments revenue per U S member off $1.44 was down 2% over the prior year's fourth quarter due to the impact of new members on boarded over the course of the year.
Excluding the dilutive impact of new member additions over the course of the year revenue per U S. Member would have increased by over 2% versus the prior year's quarter.
Revenue per U S member increased 4%.
Chile over the third quarter.
Fourth quarter adjusted EBITDA from the integrated care segment grew 31% year over year to $43 7 million.
While margins expanded 230 basis points to 12, 2%.
Adjusted EBITDA growth was driven primarily by revenue growth and leverage over G&A expense.
For the full year integrated segments revenue grew 6% to $1 4 billion adjusted EBITDA declined 6% to $135 million driven primarily by increased technology and development expense.
That'll help segment revenue increased 29% year over year in the fourth quarter to $277 million.
Primarily driven by growth in better health membership.
That'll help adjusted EBITDA grew 22% year over year to $52 8 million.
In the quarter.
Sequentially adjusted EBITDA margin expanded 15 percentage points to 19, 1%.
This margin expansion was driven in large part by the seasonality of advertising spend as we've discussed on prior calls.
For the full year that our salt segment revenue grew 41% to $1 billion.
Adjusted EBITDA declined 6% to $114 million, representing a margin of 11, 2% a reflection of the advertising market headwinds discussed last year.
Consolidated net loss per share in the fourth quarter was $23.49.
Compared to a net loss per share of seven in the fourth quarter of 2021.
Net loss per share in the fourth quarter includes a non cash goodwill impairment charge of $3 8 billion.
Our $23 26 per share.
Stock based compensation expense of 31 per share.
And amortization of acquired intangible book value per share.
The goodwill impairment charge reflects the overall operating environment, including the lower rate of growth reflected in our guidance today and.
And overall financial market conditions, including decreased market multiples.
This goodwill write off is noncash and has no impact on our financial position or our ability to invest in the business going forward.
During the fourth quarter and full year, the company generated free cash flow of $12 million and $17 million respectively.
We ended the year with $918 million in cash and short term investments on the balance sheet.
Now turning to forward guidance.
For the full year 2023.
We expect revenue to be in the range of.
2552 to $6 75 billion representing.
Representing revenue growth of 6% to 11%.
This revenue outlook contemplates mid to high single digit percentage growth in our integrated care segment.
Low double digit to mid teen percentage growth in our better health segments.
We expect total integrated care segment U S. Membership of 84 to 86 million members. We expect consolidated adjusted EBITDA for the full year to be in the range of $275 million to $325 million or growth of 20.
2% at the midpoint.
Consolidated guidance assumes year over year, adjusted EBITDA margin of flat to up 50 basis points for the integrated care segment.
An increase of 100 to 300 basis points for the better health segments.
We expect to generate free cash flow of at least $100 million in 2023, driven by both the growth in adjusted EBITDA and an expected decline in capitalized software development costs.
For the first quarter of 2023.
We expect revenue of $610 million to $625 million, representing growth of 8% to 11% year over year.
We expect adjusted EBITDA of $42 million to $50 million.
First quarter consolidated guidance contemplates low to mid single digit revenue growth for the integrated care segment.
Mid to high teens revenue growth with a better health segment.
Totally integrated care segment U S. Membership is expected to increase to 84 to 85 million members.
We expect integrated skincare segment margins to be slightly higher than better help segment margins in the first quarter.
Due to typical margin seasonality.
It's important to remind you of the seasonality dynamic in the health business.
As we have discussed throughout 2022, we typically see slower advertising spend in the fourth quarter during the holiday season.
This drives lower customer acquisition in the back half of the fourth quarter and results in the strongest seasonal margin quarter of the year for better health.
It also results in the seasonally weaker sequential growth and margins of the year in the first quarter as advertising spend is ramped up and the customer acquisition funnel rebuilt.
As such our guidance assumes the first quarter to be the low point of the year for better help margins.
And we expect consistent margin progression over the course of 2023.
With that I will turn the call back to Jason.
Thanks, Mala before we go to Q&A I also wanted to call your attention to our third annual corporate social responsibility report, we issued a few weeks ago.
While all of our work is mission driven.
The fact that our 5000 colleagues to giving back to the community as seriously as delivering for our members is a source of tremendous pride.
The report covers a wide range of areas, where we've had an impact in the past year.
From delivering more than 16000 volunteer hours, 33% more than last year to deploying 18 autonomous telehealth devices to Ukraine in cooperation with the World Telehealth initiative.
I'm grateful to my colleagues for demonstrating once again, our core corporate value, we're passionate about taking care of people.
And I encourage you to check out their report.
With that we're happy to take your questions operator.
If you would like to ask a question. Please press star followed by one on your telephone keypad.
Any reason you would like to remove that question. Please press star followed by two again to ask a question. Please press star one as a reminder, if you are using a speaker phone. Please remember to pick up your handset before asking your question.
And also on behalf of the management team, we would ask that you limit yourself to one question. We will pause here briefly as questions are registered.
Okay.
Please standby we are having some technical difficulties with the management team there'll be dialing back in soon.
Our first question comes from the line of Ryan Daniels of.
William Blair. Please proceed.
This is Jackson on for Ryan Daniels, I know youre, not giving guidance specifically towards the better health segment, but based on the better help users you outlined in your presentation deck I'm curious on your expectations when it comes to growth within the user base more longer term.
It looks like year over year fourth quarter increased pretty significantly. So do you kind of expect better help to contribute more as a percent of total revenue over time.
Do you have any longer term expectations on growth rate that would be much appreciate it. Thank you.
Yeah. So thank you for the question.
We're not in a position to give any outlook beyond 2023, we have given you.
Hopefully plenty of disclosure and details for how we expect the better health business to be.
In 2023 look.
At this point better help is over a $1 billion business.
I don't think you're going to see it return to the type of hyper growth that this business has seen over the past two years, where it grew.
Well over 100% in the past few years, but we do think importantly that there remains a long runway for growth in this market. If you think about virtual therapy, it's still underpenetrated.
And a lot of the structural issues around access on costs arent getting addressed in other places so the tailwind for this business are still very strong.
The other important thing to note is as Jason said in his remarks prepared remarks.
We're making a choice the CR to grow a little bit slower and drive margin improvement we've talked about the 100 to 300 basis points of margin improvement in this business and then the last thing I'd say is.
That'll help is still likely to add more incremental revenue this year.
Frankly, most of our competitors generate in total annual revenue.
Yes.
There is a lot of scale in this business and there's a lot of scale advantage should take to take advantage off in this business.
Yes.
Thank you. The next question comes from the line of Lisa Gill with Jpmorgan. Please proceed.
Great. Thanks, very much and good afternoon.
I wanted to start with two things Molly you made an interesting comment around how the business is progressing going forward and as you said whole person value based bundles. So first half Thats. My question for Jason can you talk to me about what Youre seeing for 2023, how do we think about how value based bundles will work.
And what that means to revenue and profit and then secondly.
You talked about the improvement in the margin.
My math, it's like 130 basis points at the midpoint of what you've given can you maybe just talk about like what are some of the key drivers to that margin improvement is it mix is it the realignment of the business like what are some of the things that we should think about that maybe are specific to 2003 or things that potentially will impact.
The margins as we think about beyond 'twenty three.
Yeah.
Yes. Thanks, Lisa there is no question that especially health plans, but also increasingly large employers are looking for us to provide value based arrangements and value based arrangements can take the form of being based on clinical outcomes being based on.
Bending the cost curve.
Or some combination of the two of them in many cases, they are multi product bundles of services from us.
And so if I look back at the last year the interest from health plans and deals with value based components is up about forex year over year.
And that I think really plays well to us our outcomes proof points are clear.
Where we are driving significantly better outcomes when consumers engaging more with more than one of our clinical products.
And we're in a fortunate position now where for our chronic care solutions, 30% of our members who are engaging with the chronic care solution are engaging with more than one of them.
But it's also true that we are driving significant return on investment for our clients and that obviously lends itself well to value based arrangements on average our diabetes program delivers a return on investment.
Three to one for our clients.
For those who are significantly hypertensive, meaning over 140.
Systolic, we're driving $58 <unk> cost avoidance.
And so again, those lend themselves to really well to aligning us with our clients and value based arrangements.
And then Lisa for your second question.
Think about our margin progression.
Bring it down to a few key factors right first is if you think about the better help margin improvement, it's really around the leverage we will get from A&M.
Moving the yield the productivity of our A&M.
More broadly if you think about.
Integrated care.
It's about technology and development expense leverage.
And as well as G&A as you know.
We took some very difficult decisions earlier this year in terms of doing a layoff.
And so if you think about the measures we are taking in controlling our costs.
It is around <unk>.
Driving G&A efficiency, it's about things such as real estate consolidation and internally. We are also driving efficiencies in our structure.
We have centers of excellence now et cetera, all of that essentially to right size, our cost base relative to the growth rate of the business.
Thank you. The next question comes from Jill interesting <unk> Securities. Please proceed.
Thank you and thanks for taking my question first a quick clarification to your comment.
Are you willing to quantify how much benefit does your guidance assume from the recent restructuring.
For 2023, and my main question, Jason I mean, you talked about the demand for that product digital health platform, increasing implies moving away from point solutions as you look across your solutions and offerings are there certain areas that solutions.
I would like to expand into to respond to that demand and how do you plan to approach that in terms of build buy or partner.
So we'll take it in order.
We've given you all enough transparency on the restructuring we did we have reduced our head count by approximately 6%.
Over 300 individuals during the first quarter to.
To be clear are the significant majority of that has been completed during the first quarter and it's fully incorporated in both our first quarter and full year guidance Yale Andrew.
And the only thing I would add to that is these actions that we're taking are we have taken.
<unk> is a period of growing investment and they will moderate the pace of expense growth for 2023, and we believe this cost structure is reflective of the current growth rate of the business. It will allow us to improve the efficiency of the organization and importantly, while still allowing us to continue to inch.
<unk> in the market that's still in relatively early innings.
And Joe Andrew with respect to your question about multi product sales and there is no question that that dominates at both our pipeline and our bookings.
70% of our bookings last year were multi product bookings, we continue to see that I think it's also reflected in the success of our primary 360 product, which acts as a hub for multiple other products for clinical services.
Our primary 360 product continues to get significant traction.
And although it's off a small base.
It will probably triple the revenue and 23 from primary 360 <unk> versus 'twenty two.
So if you think about continued expansion of clinical products and services will look to add additional products and services.
Our clinical capabilities that are complementary to both our existing chronic care portfolio as well as our primary 360 product.
The full sort of primary care spectrum, if you will.
In terms of build versus buy we will continue to look opportunistically across the market.
We look at both a speed to market.
And B have financial return on those investments with respect to deciding whether we're going to build buy or partner does.
As I think has been well documented.
There are a number of companies out there who are struggling in the current financial environment and the cost of capital is significantly higher.
As other companies go out and have to raise money.
We're staying closely attuned to that but we're not stopping our pace of internal innovation.
And so you see that for example, with the launch of our one app.
Which provides a single interface and a single consumer experience for all of our products and services and enables us to rapidly.
And relatively easily deploy additional products and clinical capabilities.
Thank you. The next question comes from the line of Stephanie Davis SVP Securities. Please proceed.
Hey, guys. Thanks for taking my question. So I've been hearing about a lot of market growth outside of you guys are virtual primary care. So that'd be helpful to walk through just the basics of the model, but primary can be sexy.
I think Brett what Youre seeing for RFP activity recently versus last year and.
If we should view the wind is all incremental or is there some cannibalization bench as folks move to whole person care versus virtual urgent care.
Yes, Thanks Stephanie.
We're very excited about the growth in primary $3 60, I mentioned, we expect tripled our revenue in 2003 that we saw in 'twenty two.
We have completed several thousand primary care visits are already this year and it's growing rapidly.
We'll deliver somewhere between five and 10 extra visits and.
In primary care.
2023 that we did in 'twenty two and the pipeline is is rich with opportunities. So I feel very good about where we are in terms of cannibalization, we really don't see cannibalization of our general medical services by by our primary 360 product there.
Are really serving very different purposes.
One is a longitudinal relationship that's really holistic.
And incorporates multiple of our products and services. The other is much more episodic.
And Jay and acute in nature.
But I think what's encouraging for us is that the combination of our chronic care solutions and mental health solutions come together with our primary 360 service.
To really provide.
That whole person care over half of our <unk> hundred 60 members are using more than two of our teladoc services, including our chronic care solutions and we really see that members with chronic disease are four times as likely.
To engage with our primary 360 product.
I think lastly, all of that is driving net promoter scores in the Seventy's for RP 360 product, which is not only providing new opportunities for us, but also expansion opportunities with existing clients. The thing I'll add is we are in the very early innings for.
Virtual primary care.
But we do think based on the momentum we are seeing over time. It has the potential to suddenly become a much larger portion of the business.
The pace of adoption over the next several years is certainly going to have an impact on the integrated care segment growth in particular.
So taking that comment in mind, the tripling of revenues the primary 360.
How can we bridge to your guidance, you've got $200 million incremental revenue dollars. It's on a base with a tripling primary 360 better help any of your double digit growth.
Is there anything to call out that way.
<unk> from benefiting from the growth rate.
Well remember Stephanie that primary 360 is off a very small base in 'twenty two.
I think we're consistent about saying over the course of last year.
And we have given.
Indication of the growth rates.
The integrated care segment as well as better help segment.
So I think you can you can bring those together to look at what the overall guidance, we've given for 23 years.
Yes.
Thank you. The next question comes from the line of Richard close and the just a friendly reminder, the management team is X that we limit each person to one question.
Richard Your line is now open you May proceed with your question.
Great. Thanks for the question I appreciate that Marlin can you talk a little bit more about the integrated margins, what you're seeing and what you're expecting I guess, the flat to 50 basis.
<unk> just maybe.
A little bit more detail and the expansion opportunities maybe beyond.
2023 in this business.
Yeah.
So here's what I would say if you think about the integrated care segment.
We will drive leverage in our expense base as our revenue continues to grow and scale if.
If you think about what the elements of that business are.
You will see much more in the press release about the Watson integrated care segment, but it's essentially think of it as.
Growth across chronic care.
Primary <unk> hundred 60, as we've talked about our telemedicine business, including mental health on the <unk> side.
And then growth in our hospital and health system business.
So if you just think of the diversity of growth opportunities across all of these and I'm sorry. The last important one is the international right because again this is a global.
Integrated care segment. So again, if you think about the growth opportunities across all of these.
The the the margin progression will come from driving revenue and scaling revenue number one and number two as we've talked about.
Just being much more efficient in our cost and expenses in that segment, whether it be.
Technology and development expense, we are going to drive leverage in T&D expense this year.
And we expect we will expect to continue to do that in future years, we are still investing to be clear in the business. Given the fact that we are still in the early innings, but we do expect to drive leverage there and as I said in.
SG&A as well so it's a combination of those that will drive the margin progression in the integrated care segment.
Thank you. The next question comes from George Hill of Deutsche Bank. Please proceed.
Yes, Hi, Maxion for George Thanks for taking the question.
Your provider model has been gradually changing from a pure contract model to a more of a hybrid model.
Can you give us some color on where you are now in terms of contracted versus import providers and how do you how do the restructuring and cost saving initiatives change this ratio and the pace of hiring to support membership growth. Thank you.
Yes. So we are in the process, we haven't given out a percentage of total visits that are being taken by employed versus.
Our independent contractor physicians.
But we are in the process of shifting I think you will see us go to north of 50% of our visit volume ultimately being taken by employed physicians.
We've proven now is that we can drive actually greater physician productivity at higher consumer net promoter scores.
And.
Equally to better clinical integration of all of our products. When we do that with an employed physician model will never get to 100%.
And that wouldn't be prudent because it's not you get you get beyond the efficiency front.
Tier at some point.
And.
And more and more we are also moving to <unk>.
Employed physicians for both our general medical more episodic.
As well as of course for our more longitudinal relationships and primary $3 60.
I wouldn't point you to that transition when we talked about the restructuring that.
That we did at the beginning of this year that was really not oriented around our physician staffing model.
More it was around our opex.
And around our.
Our non clinical staff.
Thank you. The next question comes from Jessica Tucson of Piper Sandler. Please proceed.
Hi, Thank you guys for taking the question.
I just was hoping.
You could help us square the increase in multi product sales with the kind of flattish average revenue per U S integrated care member.
Over the course of 2022 relative to that <unk> 21.
You presented and then just secondarily, Jason if you could just remind us what's the level or type of behavioral care and care navigation, that's embedded in the primary <unk> offering.
Thank you.
So if you what we said in our prepared remarks, Jeff is.
You think about the revenue per member and you talk about flattish again.
Remember, we on boarded a lot of new members in 2022, and there is a diluted impact of that do you think about the growth in membership last year.
About 6% to 7% growth in members. So there is a diluted impact if you if you normalized for that impact as we said on a year over year basis, we did see an increase in revenue per member.
<unk>, 2% increase and it translated to about four sequentially. The point being that we are actually seeing the impact of the revenue growth and the different elements and components of that.
<unk> revenue per member and again, if you think about what is included in that in that revenue per member.
It is increases in enrollment is increases in visit utilization.
Increases in the growth in our Hoffman on health systems business. As we said it is overall segment revenue growth and the different components of that that will drive the increase in revenue per member.
And then with respect to primary 360, our standard offering for primary $3 60 delivers mental health along with virtual primary care that mental health is tends to be therapy, as well as access to psychiatry for medication management.
Having said that not every client it takes there are standard or a full bundle of services.
And so while while that is our lead offering.
Just caution you that not every product every client takes the same bundle of services.
Thank you. The next question comes from the line of Daniel gross weight of Citi. Please proceed.
Hey, guys. Thanks for taking my question as we talk to benefits managers around virtual primary care. It seems like the integration of virtual and physical clinics has become increasingly important I'm sure you hear the same thing can you remind us how you guys integrate with within personal care and if Youre integration strategy has changed at all.
Yes, Daniel Thanks for the question I think about it in terms of sort of three can central concentric circles at.
At the center is what we can deliver virtually for the consumer.
All of the dimensions, including primary care mental health chronic care.
Longitudinal and holistic manner. The second ring is around what can be delivered in the home and so more and more we are driving care into the home and helping to facilitate care that can be delivered in the home whether thats diagnostic testing.
Or actual delivery of care in the home and then the third ring is referrals into the delivery system.
And we always work with our clients to strive to create the most efficient referral into the physical delivery system when someone needs to be referred.
Doug.
The question of do I think that sometimes behind that is do you want to own brick and mortar. So that you can refer into your own brick and mortar facilities and I really don't I don't think that that's a highly scalable model.
And I think in some cases, it can provide perverse incentives to failure owned beds and failure on brick and mortar capacity, rather I'd rather be in the business of making sure that we are making the best referral. The first time for the highest clinical outcomes and the greatest impact on cost of care.
Thank you. The next question comes from Stan Bernstein of Wells Fargo. Please proceed.
Hi, Thanks for taking my questions.
I appreciate the additional color on better health is very helpful.
Maybe on <unk>.
Take care since nobody asked.
2020 was a pretty big enrollment year full commentary I'm. Just wondering are any of those contracts coming up for renewal and maybe if you can comment on what your visibility is in that segment over the next year or two.
So.
As we have.
Don are very detailed planning as we always do.
For 2023, I would say.
We have a high degree of visibility into.
Our chronic care contracts.
Importantly, as we have.
That guidance.
We have been reasonably prudent about how much in your revenue to expect from <unk>.
On the integrated side.
Segment.
Including chronic care.
So I would say that the level of visibility that we have is.
Hi.
And I wouldn't point to any significant contracts that are up over the course of this year.
Thank you. The next question comes from the line of Sandy Draper of Guggenheim. Please proceed.
Hi, Thanks. This is mitchell on for Sandy.
A few quick ones how are you thinking about the macro environment impact on your sales cycle and also are you seeing any impact to underlying membership of customers from the recent job cuts.
Thanks.
Yes, I'll take the first one the second one first we haven't really seen an impact.
On our membership from.
Anything that might be going on in the labor market, we're always attuned to that I'm very cognizant of the question but.
But we really haven't seen an impact in <unk>.
Some cases, where we're balanced because we participate in the commercial segments.
Exchange segments as well as the Medicaid segments. So sometimes we're insulated because we see a flow from one to the other but we're really not seeing any significant impact with respect to the buying behavior, we're more attuned to it and the better help segment.
And oriented around the sensitivity of the consumer given the macroeconomic uncertainty and certainly we've factored that into our outlook over the course of this year.
I think in the <unk> segment.
It really has the effect of sometimes slowing down in the buying process or the decision making process, but it doesn't necessarily stop it all together I think if anything it focuses the buyer on where they are getting the most value.
And we believe that we rise to the top and that kind of an environment.
Thank you. The next question comes from Elizabeth Anderson Evercore. Please proceed.
Okay.
Hey, guys. Thanks, so much for the question.
If you could give us a little bit more detail on better health like how are you sort of seeing <unk> are you seeing any changes or attention compared to a year ago versus the macro environment.
Change in AD spend and then I was wondering if you could also give us an update on the group therapy session and how those are continuing to Chad. Thank you.
Yeah. So no changes really in any of those underlying metrics if I think about.
One moment, we are experiencing technical difficulties the management team will be back in a few moments.